申请人:Davidson Alan Hornsby
公开号:US20090291978A1
公开(公告)日:2009-11-26
Compounds of formula (I) are inhibitors of histone deacetylase activity, and are useful in the treatment of, for example, cancers, wherein R
1
is a carboxylic acid group (—COOH), or an ester group which is hydrolysable by one or more intracellular carboxyesterase enzymes to a carboxylic acid group; R
2
is the side chain of a natural or non-natural alpha amino acid; Y is a bond, C(═O)—, —S(═O)
2
—, —C(—O)O—, —C(O)NR
3
—, —C(═S)—NR
3
, —C(═NH)NR
3
or —S(═O)
2
NR
3
— wherein R
3
is hydrogen or optionally substituted C
1
-C
6
alkyl; L is a divalent radical of formula -(Alk
1
)
m
(O)
n
(Alk
2
)
p
— wherein m, n and p are independently 0 or 1, Q is (i) an optionally substituted divalent mono- or bicyclic carbocyclic or heterocyclic radical having 5-13 ring members, or (ii), in the case where both m and p are 0, a divalent radical of formula —X
2
-Q
1
- or -Q
1
-X
2
— wherein X
2
is —O—, S— or NR
A
— wherein R
A
is hydrogen or optionally substituted C
1
-C
3
alkyl, and Q
1
is an optionally substituted divalent mono- or bicyclic carbocyclic or hetero-cyclic radical having 5-13 ring members, AIk
1
and AIk
2
independently represent optionally substituted divalent C
3
-C
7
cycloalkyl radicals, or optionally substituted straight or branched, C
1
-C
6
alkylene, C
2
-C
6
alkenylene, or C
2
-C
6
alkynylene radicals which may optionally contain or terminate in an ether (—O—), thioether (—S—) or amino (—NR
A
-) link wherein R
A
is hydrogen or optionally substituted C
1
-C
3
alkyl; X represents a bond; —C(═O); or —S(═O)
2
—; —NR
4
C(═O)—, —C(═O)NR
4
—, —NR
4
C(═O)NR
5
—, —NR
4
S(═O)
2
—, or —S(═O)
2
NR
4
— wherein R
4
and R
5
are independently hydrogen or optionally substituted C
1
-C
6
alkyl; z is 0 or 1; A represents an optionally substituted mono-, bi- or tri-cyclic carbocyclic or heterocyclic ring system wherein the radicals R
1
R
2
NH—Y-L
1
-X
1
—[CH
2
]
z
— and HONHCO-[LINKER]- are attached different ring atoms; and -[Linker]- represents a divalent linker radical linking a ring atom in A with the hydroxamic acid group CONHOH, the length of the linker radical, from the terminal atom linked to the ring atom of A to the terminal atom linked to the hydroxamic acid group, is equivalent to that of an unbranched saturated hydrocarbon chain of from 3-10 carbon atoms.
式(I)的化合物是组蛋白去乙酰化酶抑制剂,可用于治疗癌症等疾病,其中R1是羧酸基(-COOH)或一个可被一个或多个细胞内羧酸酯酶水解为羧酸基的酯基;R2是天然或非天然α氨基酸的侧链;Y是键,C(═O)—,—S(═O)2—,—C(—O)O—,—C(O)NR3—,—C(═S)—NR3,—C(═NH)NR3或—S(═O)2NR3—,其中R3是氢或可选择性取代的C1-C6烷基;L是式-(Alk1)m(O)n(Alk2)p-的二价基团,其中m、n和p分别独立为0或1;Q是(i)一个可选择性取代的二价单环或双环碳环或杂环基团,其具有5-13个环成员,或(ii)在m和p都为0的情况下,是式—X2-Q1-或-Q1-X2—的二价基团,其中X2是—O—,S—或NRA—,其中RA是氢或可选择性取代的C1-C3烷基,Q1是一个可选择性取代的二价单环或双环碳环或杂环基团,其具有5-13个环成员,Alk1和Alk2独立地表示可选择性取代的二价C3-C7环烷基基团,或可选择性取代的直链或支链C1-C6烷基、C2-C6烯基或C2-C6炔基基团,其可以选择性地包含或终止于醚(-O-)、硫醚(-S-)或氨基(-NRA-)链,其中RA是氢或可选择性取代的C1-C3烷基;X表示键,—C(═O);或—S(═O)2—;—NR4C(═O)—,—C(═O)NR4—,—NR4C(═O)NR5—,—NR4S(═O)2—或—S(═O)2NR4—,其中R4和R5独立地为氢或可选择性取代的C1-C6烷基;z为0或1;A表示可选择性取代的单环、双环或三环碳环或杂环系统,其中基团R1R2NH—Y-L1-X1—[CH2]z—和HONHCO-[LINKER]-附着于不同的环原子上;-[Linker]-表示连接A中的一个环原子与羟酰胺酸基团CONHOH的二价连接基团,连接基团的长度,从连接到A环原子的末端原子到连接到羟酸胺基团的末端原子,相当于3-10个碳原子的直链饱和烃链的长度。